Invaio Sciences
Active#5 worldwide · Biological inputsDevelops natural peptides and bio-based actives delivered by trunk injection and precision application to treat tree-crop diseases such as citrus greening and Xylella.
Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| Biological inputs · worldwide | Top 32 | #5 | Edition 0 · Oct 2026 | 12 Feb 2027 |
Estimated valuation
AI · Biological inputs ranking (worldwide)- Anchor
- Last known equity round: Series C · USD 88.9M · May 2021
An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method
Funding history
| Date | Round | Amount | Type | Investors |
|---|---|---|---|---|
| May 2021 | Series C | USD 88.9M | Equity | Flagship Pioneering, Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments |
Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of Invaio Sciences as a PDF. It must answer at least one of these four questions, and stick to them:
Analyses are the opinion of their authors, not of Uback. They are checked before publication.
Comparable companies in biological inputs
Full biological inputs ranking →Investors in Invaio Sciences: Flagship Pioneering · Stage 1 Ventures · Bluwave Capital · Alexandria Venture Investments
Last updated: Oct 2026Report an error
Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.